Some previous reports had favored CD25-blocking over CD25-biased IL-2cx in the context of cancer immunotherapy due to CD25 expression on CD31+ pulmonary endothelial cells, which can lead to inflammatory immune activation in lung tissue and consequent edema.53 This evidence concerns the gene PECAM1 and cancer.